NeuroGenesis
PrivateLast Round
Grant
Aug 5, 2025
Total Funding Raised
$10M
Company Overview
NeuroGenesis operates in Healthcare & Life Sciences and is based in Rochester, New York. Its latest recorded funding round was a Grant round in August 2025.
NeuroGenesis is a clinical-stage cellular therapy company that develops treatments for neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroGenesis Comparables
Compare NeuroGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Brainstorm Cell Therapeutics Inc. | 88% | |
| Regeneration Biomedical, Inc. | 88% | |
| ImStem Biotechnology | 81% |
For institutional investors. Book with your work email.
NeuroGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 5, 2025 | ||||
| Series A | Mar 11, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuroGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Excell Partners | Series A |
| National MS Society | Grant |
| Morgan Stanley | Series A |
| Rhodium Ventures | Series A |
| New York Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2025
Monthly visitors increased 72% MoM, reaching 2.3K.
- May 1, 2025
Monthly visitors grew 664% MoM, reaching 1.2K.
For institutional investors. Book with your work email.
NeuroGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroGenesis's valuation, stock price, and market status.
Is NeuroGenesis a public or private company?
NeuroGenesis is a private company.
What is the current stock price of NeuroGenesis?
NeuroGenesis is a private company, so its shares have no public market price. Caplight tracks NeuroGenesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroGenesis worth (valuation)?
Valuation information for NeuroGenesis is not publicly available.
Can I buy NeuroGenesis stock?
NeuroGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroGenesis's last funding round?
NeuroGenesis's most recent funding round was Grant on August 5, 2025.
Who are the main investors in NeuroGenesis?
Key investors in NeuroGenesis include Excell Partners, Morgan Stanley.
Will NeuroGenesis IPO soon?
No public IPO plans have been announced for NeuroGenesis.
How can I track NeuroGenesis secondary market activity?
Caplight tracks bids, offers, and trades in NeuroGenesis's shares on secondary markets.